Organoids Market By Product (Intestinal Organoid, & Hepatic Organoid), Application (Developmental Biology, & Regenerative Medicine), End-User (Biopharmaceutical Companies, Hospitals, and Diagnostic Centres), & Region for 2024-2031

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Organoids Market Valuation – 2024-2031

The organoid market is booming, thanks to a number of major drivers. One significant driver is the growing need for tailored medication. Organoids, 3D models made of stem cells that resemble genuine organs, are an effective tool for studying individual patients’ ailments and designing specific treatments. The market size to surpass USD 1386.57 Million value in 2024 to reach a valuation of around USD 6022.63 Million by 2031.

This method has also shown promise in developing medication and minimizing animal testing dependency. Researchers can utilize organoids to evaluate the efficacy and safety of new pharmaceuticals in a more human-like context, thereby speeding up the research process while simultaneously addressing ethical concerns. These improvements drive enormous investment in the organoid business, with researchers and companies recognizing the technology’s vast potential. The rising demand for cost-effective and efficient Organoids is enabling the market grow at a CAGR of 22.23% from 2024 to 2031.

Organoid MarketDefinition/ Overview

An organoid is a miniaturized, three-dimensional (3D) structure grown in a lab that mimics some of the key properties of an organ. They are typically derived from stem cells, which have the potential to develop into many different cell types. As the stem cells grow and divide, they can self-organize into complex structures that resemble real organs.

These structures resemble miniature organs that range in size from the width of a hair to five millimeters. They have the ability to enhance the 3D construction of tumor growth to enhance the progression of tumor cells and help discover new anti-cancer treatments. Tumor spheroids are able to closely reproduce the basic properties of solid human tumors

Over the past decade, organoids have seen increasing use in various applications, such as disease modeling, understanding pathogenesis, drug screening, and regenerative medicine. This trend is expected to persist in the coming years. Recent advancements in organoid technologies have significantly contributed to creating in vitro physiological systems that accurately model their tissue of origin, surpassing conventional methods.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Growing Focus on Developing Alternatives for Animal Testing Models Drive the Organoid Market?

In the organoid market, the increased emphasis on discovering alternatives to animal testing models is propelling. Traditional animal models have long been utilized in biomedical research and medication development, but their ability to correctly anticipate human reactions is generally limited due to species differences.

This has resulted in a push for more human-relevant models, and organoids, which are smaller and simplified replicas of human organs developed in vitro, provide a viable solution. They offer a more precise picture of human physiology and illness, thereby improving the predictability and reliability of preclinical research. This change is motivated by both scientific and ethical grounds, as organoids lessen reliance on animal experimentation while also addressing concerns about animal welfare.

Furthermore, regulatory bodies and the general public are increasingly calling for reducing the use of animals in research, which is driving demand for alternative approaches like as organoids. Organoids can imitate complex human tissue structures and functions, making them suitable for researching disease causes, medication responses, and toxicity testing in a more ethical and sustainable way.

The ability to generate organoids from patient-specific cells also increases their importance in personalized medicine, allowing for more targeted therapeutic methods. This combination of ethical imperatives, legal pressures, and technological developments is providing a strong impetus for the use of organoids, resulting in market expansion and innovation in this field.

Will High Cost and Technical Complexity Hamper the Organoid Market?

Okay, so making organoids isn't exactly cheap or simple. The whole development and maintenance thing, plus the market itself, really drives up the price and makes it technically challenging. You need fancy lab equipment, special materials, and a team of really skilled people just to get started, which obviously adds to the overall cost. For smaller research labs or biotech startups that don't have deep pockets, these costs can be a real deal-breaker. On top of that, growing organoids is super tricky and requires a lot of experience, which means companies without that specialized knowledge can have a hard time even getting into the field. This high cost and technical difficulty makes it harder for everyone to use organoids for research and other applications, slowing down growth in the industry.

Furthermore, the intricacy of organoid systems complicates obtaining reliable and reproducible results. Variability in the protocols and methods used to manufacture organoids might result in discrepancies, reducing the dependability of findings from organoid investigations. This lack of standardization can make it difficult to get regulatory approval and acceptability in the scientific community, as repeatability is a key component of rigorous scientific research.

As a result, despite organoids’ promising potential, their high cost and technical complexity may discourage widespread adoption, limiting the market’s ability to fully capitalize on the innovative applications of organoid technology in drug discovery, personalized medicine, and disease modeling. Addressing these difficulties through technological developments, protocol standardization, and cost-cutting methods will be essential to the continuing expansion of the organoid market.

Category-Wise Acumens

Will MNC Play a Crucial Role in the Industry Growth in the Organoids Market?

In the organoids market, Multinational Healthcare Organizations are crucial in providing high-quality care and medicines to people in developing countries. Their efforts lead to job creation, influence public policy, offer training, and build infrastructure, all focused on improving access to healthcare services and medications.

Recently, pharmaceutical companies have demonstrated strong financial performance. The increasing number of these companies and their research and development activities generate employment and require skilled personnel to maintain essential services like sterilization and infection control, which are critical for adhering to good manufacturing practices.

In 2017, the biopharmaceutical business in the United States employed around 307,585 individuals, contributing significantly to the industrial, state, and municipal economies. Expansion of biopharmaceutical businesses will emerge as a major growth driver.

Will Intestinal Organoids Contain Higher Availability for the Intestinal Organoids Segment?

The organoids market, throughout the projected period, intestinal organoids are anticipated to maintain their dominance in the market. Their prevalence is largely attributed to their greater accessibility compared to other types of organoids. In 2023, intestinal organoids commanded a substantial market share of 37.42%.

Organoid cultures, inclusive of intestinal organoids, play a pivotal role in toxicology, drug discovery, and cancer research endeavors. Their growth patterns resembling tumors facilitate their cultivation, yielding a substantial quantity of uniform cells.

Their reliability and consistency underpin their sustained prevalence and importance within the market, driving their continued adoption and utilization in various research fields. The ability to replicate tumor-like characteristics in a controlled environment facilitates the exploration of drug responses and disease mechanisms, contributing significantly to advancements in biomedical research.

Gain Access into Organoid Market Report Methodology

Country/Region-wise Acumens

Will the Adoption of Organoid-Based Examination Models Drive the North American Region?

North America is projected to retain its status as a highly appealing market in the foreseeable future. A key factor fueling this growth is the substantial healthcare expenditure in the United States. In 2019, healthcare spending in the U.S. surged by approximately 4.6%, surpassing the broader economic growth rate of 4.0%.

The United States continues to be one of the largest markets for biopharmaceuticals globally, making it a lucrative area for organoid manufacturers. The country dominates the organoids industry, largely due to the increased adoption of organoid-based examination models in the biotechnology sector across both the United States and Canada.

These advanced models have addressed the limitations of traditional 2D cell cultures by providing a 3D microenvironment that closely mimics human tissue structures.

This advancement allows for more accurate predictions of in vivo test results. The high per capita healthcare spending and favourable healthcare policies in the United States have further supported the integration of organoid technologies. As a result, the United States held a significant market share of 46.1% in the organoids market in 2023.

Will the Growing Number of Scientists and Research Institutions Accelerate Asia Pacific?

The Asia Pacific region is emerging as a significant player in the organoid market, fueled by several factors driving its rapid growth and expansion.

The research landscape in Asia-Pacific countries such as India, China, and Japan are flourishing, leading to a growing number of scientists and research institutions. This expansion facilitates extensive exploration of organoids’ potential, advancing the field through diverse and robust scientific inquiry.

Countries like India and China in the Asia-Pacific region are experiencing increased healthcare spending, which drives investments in cutting-edge medical technologies, including organoids. This financial boost supports the development and adoption of innovative healthcare solutions.

The Asia-Pacific region faces a rising incidence of chronic diseases, driving the need for enhanced drug discovery and personalized medicine approaches. Organoids, with their potential to mimic human tissue and disease conditions accurately, offer significant promise in addressing these healthcare challenges.

Competitive Landscape

The organoid market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are actively working to solidify their presence through strategic initiatives such as collaborations, mergers, acquisitions, and leveraging political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the battery separator market include

  • Cellesce Ltd
  • DefiniGEN
  • Qgel
  • Hubrecht Organoid Technology (HUB)
  • OcellO B.V.
  • STEMCELL Technologies Inc.
  • Thermo Fischer Scientific Inc.
  • Organovo Holdings Inc.
  • Takara Bio Inc.
  • Corning Incorporated
  • 3Dnamics Inc.

Latest Development

  • In September 2020, Hubrecht Organoid Technology (HUB) and BGI-Qingdao inked a Memorandum of Understanding (MoU) to establish a collaborative effort aimed at establishing a joint Next Generation Diagnostics (NGD) center in China. This collaboration aims to enhance personalized care, improve treatments, accelerate the development of new medications, and promote safer medicines.
  • In January 2021, BIOIVT forged an exclusive global commercial distribution partnership with Upcyte Technologies GmbH for its cell products and media, encompassing cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
  • In May 2023, Next&Bio Inc., a company specializing in establishing an organoid-based precise medicinal search and development framework, signed a Memorandum of Understanding (MOU) with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS). The agreement outlines plans for a joint venture aimed at advancing innovative precision medicine treatments using cancer-organoids.

Report Scope

Report AttributesDetails
Study Period

2021-2031

Growth Rate

CAGR of ~22.23% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2021-2023

Forecast Period

2024-2031

Quantitative Units

Value in USD Million

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Product
  • Application
  • End-Users
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Key Players

Cellesce Ltd, DefiniGEN, Qgel, Hubrecht Organoid Technology (HUB), OcellO B.V., STEMCELL Technologies Inc., Thermo Fischer Scientific Inc., Organovo Holdings Inc., Takara Bio Inc., Corning Incorporated, 3Dnamics Inc.

Customization

Report customization along with purchase available upon request

Organoid Market, By Category

Product

  • Intestinal Organoids
  • Hepatic Organoids
  • Pancreatic Organoids
  • Colorectal Organoids
  • Neural Organoids

Application

  • Bio-banking
  • Biomedical Research and Drug Discovery
  • Regenerative Medicine
  • Cancer Research
  • Therapeutic Tools

End User

  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Academics and Research Institutes

Region

  • North America
  • Asia- Pacific
  • Europe
  • Rest of World

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We'll dig into the market with both qualitative (think insights!) and quantitative (numbers!) analysis, breaking things down using segments that look at money and beyond. You'll get the scoop on market value, with USD Billion figures for every segment and sub-segment. We'll even pinpoint the region and segment expected to grow the fastest and be the biggest. Get ready for a geographic breakdown, showing where the product/service is being used and the factors influencing the market in each area. We'll also map out the competitive scene, ranking the big players and covering new launches, partnerships, expansions, and acquisitions from the last five years. Our detailed company profiles will include company overviews, insights, product comparisons, and SWOT analyses. We'll give you the current and future outlook of the industry, highlighting growth opportunities, drivers, and challenges in both emerging and developed regions. Plus, we'll dive deep with Porter's five forces analysis and walk you through the Value Chain to give you a complete picture. We'll lay out the market dynamics and point to growth opportunities on the horizon. And to top it off, you'll get 6 months of analyst support after the sale!

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.

Pivotal Questions Answered in the Study

Some of the key players leading in the market include STEMCELL Technologies Inc., Hubrecht Organoid Technology, Definigen, Cellesce Ltd, Tishcon Corp, and OcellO B.V.
The rising investments in research and development, growing demand for personalized medicine, and supportive government initiatives and funding are a few factors that are driving growth in the market.
The organoid market is estimated to grow at a CAGR of 22.23% during the forecast period.
The organoid market was valued at around USD 1386.57 Million in 2024.

Related Reports

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email